AI-based drug developer Basecamp valued at $800 million after $140 million funding round
The oversubscribed round will fund next-generation EDEN models and AI-designed therapies for cancer and autoimmune diseases, the company said.
- On Wednesday, September 23, 2026, London-based Basecamp Research announced it raised $140 million in a Series C funding round, valuing the AI-based drug developer at $800 million.
- The oversubscribed financing, led by S32, will fund the development of the company's EDEN models, which are trained on its proprietary Trillion Gene Atlas dataset collected across more than 30 countries.
- Investors including NVIDIA, Anthropic, and the Rockefeller Foundation joined the round, while S32 General Partner Andy Conrad, former CEO of Google's Verily, joins the Basecamp board of directors.
- Basecamp aims to develop in vivo cell therapies for cancer and autoimmune diseases, seeking to lower costs compared to current treatments that the company said cost "hundreds of thousands of dollars per patient."
- While the company has demonstrated strong preclinical results, Basecamp co-founder and CEO Glen Gowers said the funding brings this technology closer to patients, though no clinical trial timeline was provided.
14 Articles
14 Articles
AI-based drug developer Basecamp valued at $800 million after $140 ...
PR Newswire
Basecamp Research raises $140M to advance AI-designed therapeutics
/PRNewswire/ -- Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation...
Basecamp Research raises $140M for AI-designed cell therapies - European Biotechnology Magazine
London-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. Its first focus is in vivo cell therapy.
Basecamp Research raises $140M to advance AI-designed therapeutics - Business News Week
Oversubscribed Series C led by S32 with backing from NVIDIA and others Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships The company has demonstrated strong preclinical results across multiple modalities and disease areas LONDON and BOSTON, Sept. 23, 2026 /PRNewswire/ — Basecamp Research, a frontier AI company […] The post Basecamp Research raises $140M to ad…
Inside Basecamp Research, the AI startup turning evolution into training data
Basecamp Research has raised $140 million from investors including Nvidia and Anthropic's Anthology Fund. The London company trains AI models on genetic material from rainforests, oceans, and hot springs to design antibiotics and tools for cell therapies. In an interview with THE DECODER, CTO Philip Lorenz explains why biology is a far bigger problem for AI than language, and why good scores on paper don't guarantee good molecules. The article I…
Basecamp Research has collected 140 million US dollars, including from Nvidia and Anthropics Anthology Fund. The London-based company trains AI models with genetic material from rainforests, seas and hot springs to design antibiotics and tools for cell therapies. In an interview with THE DECODER, Chief of Technology Philip Lorenz explains why biology is a much bigger problem for AI than language and why good benchmarks don't guarantee good molec…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
